The Quality Policy of the Medicines Control Authority of Zimbabwe (MCAZ) is to ensure the provision of accurate and timeous services, continuously meet requirements of our customers and guarantee patient safety as stated in the Medicines and Allied Substances Control Act (Chapter 15:03). This enables the Authority to be an effective medicines regulator in Zimbabwe and a leading regulatory authority in the world. MCAZ is committed to protecting the public and animal health by ensuring that accessible medicines, allied substances and medical devices are safe, effective and of good quality. This is achieved by carrying out activities in accordance with the relevant procedures and specifications.
In this issue:
MCAZ turns 20 years
Basics of reporting Side Effects of medicines Electronic Adverse Drug Reaction Reporting
Increased Reporting from the Targeted Spontaneous Reporting (TSR) Programme
The aims of the PV policy handbook are to firstly provide a framework for a national
pharmacovigilance system in Zimbabwe. Secondly, to define the pharmacovigilance activities undertaken by the Pharmacovigilance centre and stakeholders. Thirdly to delineate the trends and signals of adverse events with medicines used in the country and help policy makers utilize evidence-based practice in patient safety and therapeutics.